Arch Therapeutics, Inc. – OTC:ARTH
Arch Therapeutics stock price today
Arch Therapeutics stock price monthly change
Arch Therapeutics stock price quarterly change
Arch Therapeutics stock price yearly change
Arch Therapeutics key metrics
Market Cap | 1.43B |
Enterprise value | 696.74M |
P/E | -0.74 |
EV/Sales | 40468.59 |
EV/EBITDA | -155.81 |
Price/Sales | 40251.17 |
Price/Book | -117.68 |
PEG ratio | -0.03 |
EPS | -3.07 |
Revenue | 101.33K |
EBITDA | -4.64M |
Income | -6.76M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | -32094.81% |
Oper. margin | -31798.4% |
Gross margin | -203.96% |
EBIT margin | -31798.4% |
EBITDA margin | -4582.67% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeArch Therapeutics stock price history
Arch Therapeutics stock forecast
Arch Therapeutics financial statements
| Mar 2023 | 16.65K | -1.01M | -6092.59% |
|---|---|---|---|
| Jun 2023 | 13.29K | -1.82M | -13714.79% |
| Sep 2023 | 39.51K | -2.45M | -6218.07% |
| Mar 2024 | 31.86K | -1.46M | -4610.37% |
| 2025 | 221.95M | 31.94M | 14.39% |
|---|---|---|---|
| 2026 | 328.87M | 46.51M | 14.14% |
| 2027 | 44.32M | 4.79M | 10.82% |
| 2028 | 55.98M | 5.96M | 10.65% |
Analysts Price target
Financials & Ratios estimates
| Mar 2023 | 1592729 | 7.97M | 500.95% |
|---|---|---|---|
| Jun 2023 | 1564246 | 9.57M | 612.39% |
| Sep 2023 | 1958189 | 9.46M | 483.4% |
| Mar 2024 | 1540067 | 12.41M | 806.3% |
| Mar 2023 | -599.86K | 0 | 618.74K |
|---|---|---|---|
| Jun 2023 | -897.54K | 0 | 954.59K |
| Sep 2023 | -1.22M | -4.52K | 1.36M |
| Mar 2024 | -700.15K | 0 | 520.73K |
Arch Therapeutics alternative data
| Aug 2023 | 8 |
|---|---|
| Sep 2023 | 8 |
| Oct 2023 | 8 |
| Nov 2023 | 8 |
| Dec 2023 | 8 |
| Jan 2024 | 8 |
| Feb 2024 | 8 |
| Mar 2024 | 8 |
| Apr 2024 | 8 |
| May 2024 | 8 |
| Jun 2024 | 8 |
| Jul 2024 | 8 |
Arch Therapeutics other data
| Period | Buy | Sel |
|---|---|---|
| Aug 2023 | 27446 | 0 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Purchase | HICKS LAURENCE director | Common Stock | 10,292 | $0.28 | $2,830 | ||
Purchase | ABRAMS MICHAEL S officer: CHIEF FINANCIAL OFFICER | Common Stock | 10,292 | $0.28 | $2,830 | ||
Purchase | NORCHI TERRENCE W director, officer.. | Common Stock | 6,862 | $0.28 | $1,887 | ||
Purchase | SULAT JAMES R director | Series J Warrant (right to buy) | 340,910 | N/A | N/A | ||
Option | SULAT JAMES R director | Common Stock | 30,000 | $0.37 | $11,100 | ||
Option | SULAT JAMES R director | Stock Option (right to buy) | 30,000 | $0.37 | $11,100 | ||
Purchase | SULAT JAMES R director | Common Stock | 111,111 | N/A | N/A | ||
Purchase | SULAT JAMES R director | Series E Warrant to Purchase Common Stock | 83,333 | $0.44 | $36,500 |
| Insider | Compensation |
|---|---|
| Dr. Terrence W. Norchi M.D. (1965) Co-Founder, Chairman, Pres, Chief Executive Officer & Sec. | $477,530 |
Mr. Michael S. Abrams (1970) Chief Financial Officer | $345,040 |
Mr. Daniel M. Yrigoyen (1969) Vice President of Sales | $291,730 |
-
What's the price of Arch Therapeutics stock today?
One share of Arch Therapeutics stock can currently be purchased for approximately $0.
-
When is Arch Therapeutics's next earnings date?
Unfortunately, Arch Therapeutics's (ARTH) next earnings date is currently unknown.
-
Does Arch Therapeutics pay dividends?
No, Arch Therapeutics does not pay dividends.
-
How much money does Arch Therapeutics make?
Arch Therapeutics has a market capitalization of 1.43B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 383.8% to 75.72K US dollars.
-
What is Arch Therapeutics's stock symbol?
Arch Therapeutics, Inc. is traded on the OTC under the ticker symbol "ARTH".
-
What is Arch Therapeutics's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Arch Therapeutics?
Shares of Arch Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Arch Therapeutics's key executives?
Arch Therapeutics's management team includes the following people:
- Dr. Terrence W. Norchi M.D. Co-Founder, Chairman, Pres, Chief Executive Officer & Sec.(age: 60, pay: $477,530)
- Mr. Michael S. Abrams Chief Financial Officer(age: 55, pay: $345,040)
- Mr. Daniel M. Yrigoyen Vice President of Sales(age: 56, pay: $291,730)
-
Is Arch Therapeutics founder-led company?
Yes, Arch Therapeutics is a company led by its founder Dr. Terrence W. Norchi M.D..
-
How many employees does Arch Therapeutics have?
As Jul 2024, Arch Therapeutics employs 8 workers.
-
When Arch Therapeutics went public?
Arch Therapeutics, Inc. is publicly traded company for more then 12 years since IPO on 20 May 2013.
-
What is Arch Therapeutics's official website?
The official website for Arch Therapeutics is archtherapeutics.com.
-
Where are Arch Therapeutics's headquarters?
Arch Therapeutics is headquartered at 235 Walnut Street, Framingham, MA.
-
How can i contact Arch Therapeutics?
Arch Therapeutics's mailing address is 235 Walnut Street, Framingham, MA and company can be reached via phone at +61 74312313.
Arch Therapeutics company profile:
Arch Therapeutics, Inc.
archtherapeutics.comOTC
8
Biotechnology
Healthcare
Arch Therapeutics, Inc., together with its subsidiaries, operates as a biotechnology company in the United States. The company develops and markets products based on its AC5 self-assembling technology platform to stop bleeding and control leaking, as well as manages wounds during surgery, trauma, and interventional care or from disease. Its flagship products include AC5 advanced wound system and AC5 topical hemostat, which are intended for skin applications, such as management of complicated chronic wounds or acute surgical wounds. The company was founded in 2006 and is based in Framingham, Massachusetts.
Framingham, MA 01702
CIK: 0001537561
ISIN: US03939W1099
CUSIP: 03939W109
